This drug is a potent inhibitor of DYRK1A in vitro, as well as in Drosophila and mouse models of DYRK1A overexpression and is currently in clinical trials for treating cancer and COVID-19 (Siddiqui-Jain et al., 2012; Kim et al., 2016; Halloran et al., 2022; Grygier et al., 2023). Here, DYRK1A is linked to COVID-19.